Walleye Trading’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-1,300
Closed -$91K 4642
2018
Q3
$91K Buy
+1,300
New +$85K ﹤0.01% 4257
2017
Q4
Sell
-4,700
Closed -$288 4345
2017
Q3
$288 Buy
4,700
+2,400
+104% +$136K ﹤0.01% 2950
2017
Q2
$122 Buy
2,300
+1,300
+130% +$63.4K ﹤0.01% 3436
2017
Q1
$49 Buy
1,000
+100
+11% +$4.65K ﹤0.01% 3786
2016
Q4
$36K Sell
900
-1,900
-68% -$81.1K ﹤0.01% 3816
2016
Q3
$136K Buy
+2,800
New +$133K ﹤0.01% 3070

Other funds holding BIB

Walleye Trading's BIB Position: Q4 2018 in Review

Walleye Trading sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2018, closing a stake of 393 shares — an estimated $27K sold.

Walleye Trading first reported a position in BIB in Q3 2016 and held it in 6 quarters. The position peaked at $27K in Q3 2018. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2018.

  • Walleye Trading reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Walleye Trading sold 393 ProShares Ultra NASDAQ Biotechnology shares in Q4 2018, an estimated $27K.
  • Walleye Trading first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and held it in 6 quarters.
  • Walleye Trading's ProShares Ultra NASDAQ Biotechnology position peaked at $27K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2018.

Based on Walleye Trading's 13F filing for Q4 2018, filed 14 Feb 2019.